Get the Daily Brief
Latest Biotech News
Eli Lilly’s VC arm leads $45M into anti‑aging biotech NewLimit
NewLimit raised $45 million in a financing round that included Lilly Ventures and S32, the company said. The funding will support clinical development of NewLimit’s programs targeting age‑related...
Anthropic rolls into life sciences — GenAI adoption accelerates in pharma
Anthropic announced a first dedicated life‑sciences product and a new team to accelerate applications of the company’s large‑language models in biology, including drug discovery and lab...
FDA approves Roche’s Gazyva: new option for lupus nephritis
The FDA granted approval to Roche’s anti-CD20 antibody Gazyva for patients with lupus nephritis, expanding treatment options for a severe form of systemic lupus that affects the kidneys. Roche...
Exelixis TKI trims death risk 20% — Phase 3 readout
Exelixis reported Phase 3 data showing its oral TKI zanzalintinib combined with Roche’s Tecentriq reduced the risk of death by 20% versus the Stivarga comparator in previously treated metastatic...
ADC showdown: Datroway and Trodelvy produce competing Phase 3 results
At ESMO, AstraZeneca/Daiichi Sankyo’s Datroway and Gilead’s Trodelvy both reported Phase 3 results for advanced triple-negative breast cancer, setting up a head-to-head efficacy and positioning...
Enhertu moves earlier — ADCs shifting into curative settings
AstraZeneca and Daiichi Sankyo disclosed data showing Enhertu has benefit when given earlier in breast cancer, supporting the drug’s move into potentially curative settings. Presentations at ESMO...
Padcev–Keytruda combo extends survival in bladder cancer
New Phase 3 data showed the antibody‑drug conjugate Padcev combined with Keytruda improved survival outcomes in locally advanced or metastatic bladder cancer. The readout, presented at ESMO,...
Boehringer, Bayer neck-and-neck in front-line HER2‑mutant lung
Boehringer Ingelheim and Bayer presented front-line data for targeted therapies in HER2‑mutant lung cancer at ESMO, with each company reporting tumor shrinkage and clinical activity in...
First‑in‑class YAP‑TEAD inhibitor shows early mesothelioma activity
Investigators at MD Anderson reported early clinical activity for VT3989, a first‑in‑class YAP–TEAD inhibitor, in heavily pretreated patients with refractory mesothelioma and other solid tumors....
BioCryst shells out $700M for Astria to chase HAE market
BioCryst agreed to acquire Astria Therapeutics for $700 million, adding navenibart—a Phase 3 injectable antibody for hereditary angioedema—to its pipeline. Management framed the deal as a bid to...
Lilly Ventures backs NewLimit in $45M anti‑aging raise
NewLimit closed a $45 million financing round that included investment from Lilly Ventures and other new backers, advancing the company’s anti‑aging pipeline. The round positions NewLimit to...
mRNA COVID shots enhance checkpoint inhibitor outcomes — MD Anderson data
Researchers from MD Anderson Cancer Center presented retrospective analyses at ESMO showing cancer patients who received an mRNA COVID‑19 vaccine within 100 days of starting immune checkpoint...
BioCryst buys Astria for $700M — HAE portfolio jumps
BioCryst Pharmaceuticals agreed to acquire Astria Therapeutics for $700 million, adding navenibart — a Phase 3 injectable antibody for hereditary angioedema (HAE) — to its pipeline. The deal...
Gene-editing stocks brace for Q3 — Intellia under the microscope
Investors in gene-editing and genetic-medicine companies are positioning ahead of third-quarter earnings and upcoming clinical readouts, with Intellia Therapeutics taking center stage after...
ADCs climbing the ladder... Enhertu and next-gen agents push into earlier disease
Data presented at ESMO show antibody-drug conjugates (ADCs) moving into earlier-stage breast cancer, with Enhertu demonstrating benefits when used pre‑operatively and next-generation ADCs showing...
Datroway vs Trodelvy — TNBC first‑line fight intensifies
Two competing antibody-drug conjugates—AstraZeneca/Daiichi Sankyo’s Datroway and Gilead’s Trodelvy—posted Phase 3 results at ESMO that both improved outcomes in first‑line metastatic...
Roche’s SERD shows benefit in non‑mutant breast cancer — trial could redraw market
Roche reported that its oral selective estrogen receptor degrader (SERD), giredestrant, demonstrated efficacy in patients without ESR1 mutations—marking the first SERD to show benefit in that...
Tubulis posts 59% response — TUB‑040 validates platform
Tubulis disclosed early clinical data showing a 59% overall response rate for its NaPi2b‑targeting ADC TUB‑040 across multiple dose cohorts in platinum‑resistant ovarian cancer and advanced...
EMBL unveils SDR‑seq: a tool to read hidden DNA regulatory code
EMBL researchers introduced SDR‑seq, a single‑cell method that sequences DNA and RNA from the same cell and exposes non‑coding regulatory regions where most disease‑associated variants lie. The...
mRNA Covid shots boost immunotherapy responses — ESMO and retrospective studies
Multiple teams reported that mRNA Covid‑19 vaccination given near the time of immune checkpoint inhibitor therapy correlated with improved outcomes in advanced cancer patients. MD Anderson...